Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer

Gouji Toyokawa; Kazuki Takada; Tetsuzo Tagawa; Fumihiko Kinoshita; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Shinkichi Takamori; Takaki Akamine; Fumihiko Hirai; Yuichi Yamada; Ryuji Hamamoto; Yoshinao Oda; Yoshihiko Maehara

doi:10.21873/anticanres.12649

Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer

Gouji Toyokawa, Kazuki Takada, Tetsuzo Tagawa, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Fumihiko Hirai, Yuichi Yamada, Ryuji Hamamoto, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.

Original language	English
Pages (from-to)	3707-3711
Number of pages	5
Journal	Anticancer research
Volume	38
Issue number	6
DOIs	https://doi.org/10.21873/anticanres.12649
Publication status	Published - Jun 2018

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.21873/anticanres.12649

Fingerprint Dive into the research topics of 'Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Toyokawa, G., Takada, K., Tagawa, T., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Takamori, S., Akamine, T., Hirai, F., Yamada, Y., Hamamoto, R., Oda, Y., & Maehara, Y. (2018). Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer. Anticancer research, 38(6), 3707-3711. https://doi.org/10.21873/anticanres.12649

Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer. / Toyokawa, Gouji; Takada, Kazuki; Tagawa, Tetsuzo; Kinoshita, Fumihiko; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Takamori, Shinkichi; Akamine, Takaki; Hirai, Fumihiko; Yamada, Yuichi; Hamamoto, Ryuji; Oda, Yoshinao; Maehara, Yoshihiko.

In: Anticancer research, Vol. 38, No. 6, 06.2018, p. 3707-3711.

Research output: Contribution to journal › Article

Toyokawa, Gouji ; Takada, Kazuki ; Tagawa, Tetsuzo ; Kinoshita, Fumihiko ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Takamori, Shinkichi ; Akamine, Takaki ; Hirai, Fumihiko ; Yamada, Yuichi ; Hamamoto, Ryuji ; Oda, Yoshinao ; Maehara, Yoshihiko. / Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer. In: Anticancer research. 2018 ; Vol. 38, No. 6. pp. 3707-3711.

@article{2752c20cb323483f9468281640a173f6,

title = "Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer",

abstract = "Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher{\textquoteright}s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.",

author = "Gouji Toyokawa and Kazuki Takada and Tetsuzo Tagawa and Fumihiko Kinoshita and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Shinkichi Takamori and Takaki Akamine and Fumihiko Hirai and Yuichi Yamada and Ryuji Hamamoto and Yoshinao Oda and Yoshihiko Maehara",

year = "2018",

month = jun,

doi = "10.21873/anticanres.12649",

language = "English",

volume = "38",

pages = "3707--3711",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer

AU - Toyokawa, Gouji

AU - Takada, Kazuki

AU - Tagawa, Tetsuzo

AU - Kinoshita, Fumihiko

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Takamori, Shinkichi

AU - Akamine, Takaki

AU - Hirai, Fumihiko

AU - Yamada, Yuichi

AU - Hamamoto, Ryuji

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/6

Y1 - 2018/6

N2 - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.

AB - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.

UR - http://www.scopus.com/inward/record.url?scp=85048221056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048221056&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12649

DO - 10.21873/anticanres.12649

M3 - Article

C2 - 29848731

AN - SCOPUS:85048221056

VL - 38

SP - 3707

EP - 3711

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -